Clinical Trials Logo

Gastrointestinal Stromal Tumors clinical trials

View clinical trials related to Gastrointestinal Stromal Tumors.

Filter by:

NCT ID: NCT00777504 Recruiting - Clinical trials for Renal Cell Carcinoma

Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors

Start date: October 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine if and how often an unexpected fast increase of disease and complaints shows after stopping the anti-angiogenetic therapy

NCT ID: NCT00769782 Completed - Metastatic Cancer Clinical Trials

Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor

GISTs
Start date: October 2008
Phase: Phase 2
Study type: Interventional

RATIONALE: Surgery may be an effective treatment for liver metastasis from a gastrointestinal stromal tumor. PURPOSE: This phase II trial is studying how well surgery works in treating patients with liver metastasis from a gastrointestinal stromal tumor.

NCT ID: NCT00767234 Terminated - Pancreatic Cancer Clinical Trials

Permission to Collect Blood Over Time for Research

Start date: August 2008
Phase: N/A
Study type: Observational

To determine whether biomarkers assessed in blood samples can be used to detect individuals at risk for developing blood clots or worsening of their underlying disease. The ultimate goal of the study is to identify key biomarkers derived from blood that are most characteristic and informative of individuals who will go on to develop a clotting complication.

NCT ID: NCT00764595 Completed - Metastatic Cancer Clinical Trials

Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor

GISTs
Start date: October 2008
Phase: Phase 2
Study type: Interventional

RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects of imatinib mesylate and to see how well it works in treating patients with liver metastasis from a gastrointestinal stromal tumor.

NCT ID: NCT00756509 Active, not recruiting - Clinical trials for Gastrointestinal Stromal Tumors

Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib

Start date: August 29, 2008
Phase: Phase 4
Study type: Interventional

The purpose of this multicenter, single-arm, exact binomial single-stage, phase II trial is to evaluate the efficacy of Nilotinib in patients with unresectable or metastatic gastrointestinal stromal tumors

NCT ID: NCT00751036 Terminated - Clinical trials for Gastrointestinal Stromal Tumors

Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg

MACS0375
Start date: June 2009
Phase: Phase 3
Study type: Interventional

The study will investigate the comparative efficacy and safety of two oral inhibitors of Kit and PDGFR: nilotinib 400 mg bid, a novel agent, and imatinib 400 mg bid, an approved agent with an established efficacy.

NCT ID: NCT00718562 Completed - Clinical trials for Gastrointestinal Stromal Tumors

Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib

Start date: September 2008
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of nilotinib in gastrointestinal stromal tumors patients who failed imatinib and sunitinib therapy.

NCT ID: NCT00718211 Completed - Clinical trials for Gastrointestinal Stromal Tumors

A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore

Start date: May 2006
Phase:
Study type: Observational

To review the characteristics and treatment of gastrointestinal tumours at the two tertiary centres in Singapore

NCT ID: NCT00716820 Completed - Clinical trials for Gastrointestinal Stromal Tumors

Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).

Start date: April 2008
Phase:
Study type: Observational

The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

NCT ID: NCT00700258 Completed - Clinical trials for Lymphoma, Mantle-Cell

Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]

STAR-TOR
Start date: February 13, 2008
Phase:
Study type: Observational

The purpose of this registry is to obtain a general view as regards efficacy, tolerability and safety issues of the Torisel®, Sutent®, and/or Inlyta® therapies in patients with advanced renal cell carcinoma, recurrent / refractory mantle cell lymphoma (MCL) and gastro-intestinal stroma tumors (GIST) under the conditions of routine use